Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Net Cash Flow (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of Net Cash Flow readings, the most recent being -$6.2 million for Q4 2024.

  • On a quarterly basis, Net Cash Flow fell 33.61% to -$6.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was $16.4 million, a 77.59% increase, with the full-year FY2025 number at $3.1 million, down 81.41% from a year prior.
  • Net Cash Flow hit -$6.2 million in Q4 2024 for Unicycive Therapeutics, up from -$9.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $39.2 million in Q1 2024 to a low of -$9.4 million in Q3 2024.
  • Median Net Cash Flow over the past 3 years was -$4.6 million (2023), compared with a mean of $837166.7.
  • Biggest five-year swings in Net Cash Flow: surged 906.93% in 2023 and later plummeted 110.89% in 2024.
  • Unicycive Therapeutics' Net Cash Flow stood at -$6.1 million in 2022, then rose by 23.67% to -$4.6 million in 2023, then crashed by 33.61% to -$6.2 million in 2024.
  • The last three reported values for Net Cash Flow were -$6.2 million (Q4 2024), -$9.4 million (Q3 2024), and -$7.2 million (Q2 2024) per Business Quant data.